Analysis of journal statistics on original research articles from China published in Cardiovascular Research shows that there was a 20% increase in accepted papers from China in 2017 compared with the previous years. Indeed, this is a reflection of the rapid development in the basic research of cardiovascular diseases in China these past few years. that another proteoglycan, related to bone homeostasis, osteoglycin (OGN) plays a negatively regulating role in ischemia-induced angiogenesis by inhibiting VEGF-VEGFR2 signalling, suggesting OGN may be a novel therapeutic target for ischaemic vascular diseases. Aortic dissection (AD) is a potentially fatal pathologic process within the aortic wall and its mechanisms still remain largely unknown. Pan et al. 6 have performed an explorative study of the DNA methylation bead arrays to analyse 21 ascending aorta samples underpinning AD and bicuspid aortic valve (BAV). Results reveal that both diseases are characterized by a loss of DNA methylation at non-CpG sites and distinct DNA methylation landscapes at CpG sites. The integrative analysis further reveals BAV as characterized mainly by hypermethylation at sites marked by repressive chromatin, while AD is characterized by a dedifferentiated smooth muscle cell phenotype. Of particular, AD is associated with an inflammatory vascular remodelling process, possibly mediated by the epigenome and linked to environmental risk factors such as smoking. Pulmonary arterial hypertension (PAH) is a rare disorder with a poor prognosis and pathologically characterized by progressive pulmonary arterial remodelling with the aberrant accumulation of extracellular matrix (ECM) proteins. However, the molecular mechanisms that regulate ECM remodelling and deposition in the pulmonary vasculature have not been fully elucidated. Jia et al.
Inflammation following cardiovascular injury is driven by monocytes accumulating and differentiating into distinct macrophage subsets in response to post-infarction ventricular remodelling. Wang et al. 1 show that the GABA A receptor activity of monocytes/macrophages can potently modulate post-infarction inflammation, which provides a novel target to modulate post-infarction inflammation. In addition, macrophage migration inhibitory factor (MIF), as an important proinflammatory mediator, is able to directly induce vascular smooth muscle cell (VSMC) dedifferentiation in cardiovascular pathogenesis by a p68-serum response factor axis. 2 Recent studies implicated sirtuin 1 (SIRT1) in the inhibition of inflammatory responses and Sm22a knockout results in an increased expression of pro-inflammatory factors. Shu et al. 3 have clarified the relationship between SM22a and SIRT1 in vascular inflammation. Their results demonstrate that in response to TNF-a stimulation, casein kinase (CK)II-SIRT1-SM22a acts in a loop to reinforce the expression of SM22a, and limits the inflammatory response in VSMCs in vivo and in vitro. Myocardial regeneration after myocardial infarction is also recognized as an exciting issue. The findings by Chen et al. 4 indicate that a lack of periostin (osteoblast-specific factor) impairs post-MI regeneration of cardiomyocytes and angiogenesis, with its effects mediated by the PI3K/ GSK3b/cyclin D1 signalling pathway. Interestingly, Wu et al. 5 have found that another proteoglycan, related to bone homeostasis, osteoglycin (OGN) plays a negatively regulating role in ischemia-induced angiogenesis by inhibiting VEGF-VEGFR2 signalling, suggesting OGN may be a novel therapeutic target for ischaemic vascular diseases. Aortic dissection (AD) is a potentially fatal pathologic process within the aortic wall and its mechanisms still remain largely unknown. Pan et al. 6 have performed an explorative study of the DNA methylation bead arrays to analyse 21 ascending aorta samples underpinning AD and bicuspid aortic valve (BAV). Results reveal that both diseases are characterized by a loss of DNA methylation at non-CpG sites and distinct DNA methylation landscapes at CpG sites. The integrative analysis further reveals BAV as characterized mainly by hypermethylation at sites marked by repressive chromatin, while AD is characterized by a dedifferentiated smooth muscle cell phenotype. Of particular, AD is associated with an inflammatory vascular remodelling process, possibly mediated by the epigenome and linked to environmental risk factors such as smoking. Pulmonary arterial hypertension (PAH) is a rare disorder with a poor prognosis and pathologically characterized by progressive pulmonary arterial remodelling with the aberrant accumulation of extracellular matrix (ECM) proteins. However, the molecular mechanisms that regulate ECM remodelling and deposition in the pulmonary vasculature have not been fully elucidated. Jia et al. 9 have investigated whether the activation of the receptor for advanced glycation end products (RAGE) activity contributes to the ECM modifications observed in PAH. Their results suggest that activation of RAGE facilitates the development of hypoxiainduced pulmonary hypertension by increase of ECM deposition in pulmonary arteries, and RAGE may be a potential therapeutic target for PAH treatment.
To test the effect of FKBP12.6 absence on the activation of ryanodine receptors (RyRs), Zhao et al. 10 have provided direct evidence that FKBP12.6 does stabilize the in situ operation of RyRs in intact cardiomyocytes using whole-cell patch-clamp combined with confocal imaging. They have found that FKBP12.6 loss-of-function and catecholamine stimulation synergistically over-sensitize the Ca 2þ -induced Ca 2þ release (CICR), leading to chaotic Ca 2þ waves and ventricular arrhythmias. Thus, the FKBP12.6-mediated suppression of RyR sensitivity is a key mechanism to keep the CICR system from wave generation and cardiac arrhythmia. Several mechanisms have been implicated in ischaemia-reperfusion (I/R) injury. Nevertheless, the identification of key signalling pathways of cardiac I/R injury as potential therapeutic targets remains a necessity. Wang et al. 11 have sought to determine whether and how b-arrestins (Arrbs) play a role in regulating cardiomyocyte viability and myocardial remodelling following I/R injury. They define an up-regulation of barrestin 2 (Arrb2), but not b-arrestin 1 (Arrb1), as a pathogenic factor in cardiac I/R injury, and also reveal a novel GPCR-independent mechanism of Arrb2-mediated cell death signalling in the heart. Other studies published in the 2017 issues are focused on the mechanism of neointimal formation, a hallmark of atherosclerosis and restenosis. Wu et al. 8 have investigated the effect of Semaphorin3E (Sema3E) on VSMCs migration, proliferation and neointimal formation. They have found that Sema3E/plexinD1 inhibits proliferation and migration of VSMCs via inactivation of Rap1-AKT signalling pathways. The feedback circuit between Sema3E and PDGF-BB after vascular injury contributes to the process of neointimal formation. Huang et al. 7 investigated the roles of microRNA-33 (miR-33) in neointimal hyperplasia induced by arterial mechanical stretch after vein grafting. By utilizing miR-33 mimics/ inhibitor and dual luciferase reporter assay, they have confirmed the interaction of miR-33 and BMP3. Furthermore, they have found that the miR-33-BMP3-Smad signalling pathway protects against venous SMC proliferation in response to the arterial stretch, suggesting that miR-33 could be a target that attenuates neointimal hyperplasia in grafted vessels. Overall, it is reasonable to conclude that there has been a series of noteworthy contributions from Chinese investigators to Cardiovascular Research in 2017. As this journal continues to flourish, we should anticipate more high-quality publications from China featuring diverse topics. One particular issue of importance may be exploring novel therapeutic targets and strategies to prevent the early deterioration of cardiovascular diseases and translational biomarkers to predict clinical cardiovascular risk, which requires more detailed understanding of the molecular mechanisms. Considering the mounting interest in cardiovascular research in China and the increasing impact of Cardiovascular Research, we may look forward to the rising number and improving quality of studies with high impact from Chinese investigators to be an ongoing trend for years to come.
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